Finding ways to enhance the immune response against tumors by targeting specific proteins in T cells.
Official title: Identification of molecular glues targeting FoxP3 to modulate Treg suppressive function and enhance anti-tumor immunity
Funded at Northwestern University at Chicago · NIH-10993888 · Data updated 2026-11-12
This study is looking at a way to make cancer treatments work better by targeting a protein that helps control certain immune cells, with the hope of boosting your body's ability to fight tumors during immunotherapy.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $44,187 |
| NIH project number | 1F31CA287701-01A1 |
| Project ID | NIH-10993888 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that are currently treated with immunotherapy but have not responded effectively due to high levels of Tregs.
✕Less likely to help
Patients who do not have cancer or those whose tumors are not influenced by Treg activity may not benefit from this research.
What this research studies
This research focuses on improving cancer treatment by targeting a specific protein called FoxP3, which plays a crucial role in regulating T regulatory cells (Tregs) that suppress the immune response. By chemically modifying the ubiquitin proteasome system, the researchers aim to reduce the suppressive function of Tregs, thereby enhancing the body's ability to fight tumors. The study seeks to develop new therapeutics that can more effectively modulate Treg activity, potentially leading to better outcomes for patients undergoing immunotherapy.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by improving the immune system's ability to attack tumors.
How similar studies have gone: Other research has shown promise in targeting Treg functions to enhance anti-tumor immunity, indicating that this approach could be viable.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Tang, Amy — Northwestern University at Chicago
- Study coordinator: Tang, Amy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.